ramucirumab
Selected indexed studies
- Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer. (N Engl J Med, 2025) [PMID:40454632]
- Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. (Lancet, 2014) [PMID:24933332]
- Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. (Lancet Oncol, 2014) [PMID:25240821]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer. (2025) pubmed
- Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. (2014) pubmed
- Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. (2014) pubmed
- Ramucirumab: A Review in Hepatocellular Carcinoma. (2020) pubmed
- Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. (2014) pubmed
- Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. (2019) pubmed
- Ramucirumab and its use in the treatment of hepatocellular carcinoma. (2019) pubmed
- Ramucirumab for the treatment of gastric or gastro-esophageal junction cancer. (2019) pubmed
- Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. (2019) pubmed
- Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial. (2021) pubmed